NGNE
Neurogene Inc

379
Mkt Cap
$334.11M
Volume
111,996.00
52W High
$37.27
52W Low
$6.88
PE Ratio
-4.87
NGNE Fundamentals
Price
$21.08
Prev Close
$21.57
Open
$21.50
50D MA
$19.19
Beta
1.56
Avg. Volume
177,798.54
EPS (Annual)
-$4.28
P/B
1.20
Rev/Employee
$8,644.86
$101.61
Loading...
Loading...
News
all
press releases
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday
Neurogene (NASDAQ:NGNE) will be releasing its Q4 2025 earnings before the market opens on Monday, March 23. (View Earnings Report at...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company...
Business Wire·6d ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports...
MarketBeat·7d ago
News Placeholder
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the...
Business Wire·14d ago
News Placeholder
Neurogene (NASDAQ:NGNE) Now Covered by Canaccord Genuity Group
Canaccord Genuity Group initiated coverage on shares of Neurogene in a research note on Friday. They issued a "buy" rating and a $200.00 price target on the stock...
MarketBeat·18d ago
News Placeholder
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy
Neurogene stock jumps after FDA grants Breakthrough Therapy status to NGN-401 for Rett syndrome treatment.read more...
Benzinga·18d ago
News Placeholder
Why Did NGNE Stock Surge 25% In Pre-Market Today?
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.
Stocktwits·18d ago
News Placeholder
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S...
Business Wire·19d ago
News Placeholder
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit
Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine...
MarketBeat·1mo ago
News Placeholder
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company...
Business Wire·1mo ago
<
1
2
...
>

Latest NGNE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.